Melanoma and Other Skin Cancers Research Results and Study Updates
-
First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma
In an event more than three decades in the making, FDA has approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes, or TILs.
-
Rare Melanoma Very Likely to Respond to Treatment with Pembrolizumab
People with desmoplastic melanoma, a rare form of skin cancer, are likely to benefit from treatment with a single immunotherapy drug, pembrolizumab (Keytruda), according to new results from a small clinical trial.
-
Immunotherapy before Surgery Appears Effective for Some with Melanoma
For melanoma that can be treated with surgery, a few doses of pembrolizumab (Keytruda) beforehand looks to be a good choice. In a clinical trial, people who got the presurgical immunotherapy were much less likely to have their cancer come back than those who only received it after surgery.
-
Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response
Male patients with metastatic melanoma don’t live as long as females, and their tumors are more likely to become resistant to commonly used treatments. A new study may help explain why: the androgen receptor.
-
Study Adds to Debate about Screening for Melanoma
Regular skin cancer screening leads to many diagnoses of very early-stage melanomas, results from a new study suggest. The results add to a debate about whether screening is fueling an overdiagnosis of melanoma in the United States.
-
Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3
The immunotherapy treatment, which combines the LAG-3 inhibitor relatlimab and PD-1 inhibitor nivolumab, becomes the first new immune checkpoint inhibitor approved in 8 years. Both drugs are given to patients via a single infusion to treat advanced melanoma.
-
Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain
Melanoma cells that travel to the brain produce their own amyloid beta, helping the cells survive and form metastases, a new study in mice shows. The Alzheimer’s-linked proteins appear to tamp down the brain’s immune response to the cancer cells.
-
A high-fiber diet may improve the response of melanoma patients to immunotherapy
NCI researchers have found that a diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome. The new findings come from an analysis of people with melanoma and mouse models of the disease.
-
Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma
Clinical trial finds that ipilimumab (Yervoy) and nivolumab (Opdivo) combo is superior to a combination of the targeted therapies dabrafenib (Tafinlar) and trametinib (Mekinist) as the first treatment for metastatic BRAF-positive melanoma.
-
Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning
Trial results show patients who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove high-risk stage II melanomas were less likely to have the cancer come back than those who received no treatment after surgery.
-
Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma
People with advanced melanoma treated with two immunotherapy drugs—nivolumab (Opdivo) and a new drug called relatlimab—lived longer without their cancer getting worse than those treated only with nivolumab, results from a large clinical trial show.
-
Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors
While doctors are familiar with the short-term side effects of immune checkpoint inhibitors, less is known about potential long-term side effects. A new study details the chronic side effects of these drugs in people who received them as part of treatment for melanoma.
-
Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma
In a large trial, tebentafusp helped patients with uveal melanoma live longer than patients who received other treatments for the disease. Uveal melanoma is an aggressive cancer of the eye, and many patients do not survive for a year once it has spread.
-
Fecal microbiota transplants help patients with advanced melanoma respond to immunotherapy
For patients with cancers that do not respond to immunotherapy drugs, the use of fecal transplants to modify the gut microbiome may help some of these patients respond to the immunotherapy drugs.
-
Melanoma Cells Are More Likely to Spread after a Stopover in Lymph Nodes
Melanoma cells that pass through the lymphatic system before entering the bloodstream are more resistant to cell death and spread more readily than cells that enter the bloodstream directly. The finding could lead to new treatment approaches.
-
Deaths from Metastatic Melanoma Drop Substantially in the United States
After rising steadily for decades, the number of people in the United States who die each year from the skin cancer melanoma has dramatically dropped in recent years, results from a new study show. Learn what has contributed to the dramatic decline.
-
Changes in Metabolism Help Melanomas Spread
Melanoma cells that metastasize to other parts of the body produce high levels of a protein called MCT1, a new study in mice has found. Blocking MCT1 with an investigational drug, AZD3965, led to fewer and smaller metastatic tumors.
-
Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study Finds
Researchers have developed a device that uses lasers and sound waves to scan circulating blood for melanoma cells. In a small study, the device accurately detected and reduced the amount of cancer cells in participants’ blood.
-
Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma
FDA has approved pembrolizumab (Keytruda) to treat people with Merkel cell carcinoma, a rare and deadly form of skin cancer. The approval covers use of the drug to treat locally advanced or metastatic forms of the disease.
-
Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer
The Food and Drug Administration approved the immunotherapy drug cemiplimab (Libtayo) for an advanced form of cutaneous squamous cell carcinoma (SCC), a common type of skin cancer. It is the first agent to be approved specifically for advanced SCC.
-
Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the Brain
Results from a clinical trial show that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) halted the growth of or shrank metastatic brain tumors in more than half of participants with melanoma that had spread to the brain.
-
NCI-led research team develops predictor for immunotherapy response in melanoma
In a new study, NCI-led researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a type of immunotherapy.
-
Can Age Affect Response to Immune Checkpoint Inhibitors?
A new study has linked age with how well patients with melanoma responded to treatment with immune checkpoint inhibitors. Experiments in mice suggested that the response pattern may be due to an age-related shift in the kinds of immune cells in tumors.
-
Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer
FDA recently approved the targeted-drug combination to treat patients with advanced melanoma and a subset of patients with a rare and aggressive form of thyroid cancer whose tumors have a specific mutation in the BRAF gene.
-
For Rare Melanoma, Checkpoint Inhibitors May Hold Substantial Promise
A new study suggests that patients with a rare form of melanoma, called desmoplastic melanoma, may be particularly likely to benefit from treatments known as immune checkpoint inhibitors. An NCI-sponsored clinical trial is already testing one such drug in patients with this cancer.